Heart Failure, Congestive

Cardiovascular
9
Pipeline Programs
11
Companies
17
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
4
1
2
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
1100%
+ 16 programs with unclassified modality

Competitive Landscape

11 companies ranked by most advanced pipeline stage

Rhythm Pharmaceuticals
4 programs
1
CRT-P or CRT-D DevicePhase 41 trial
Cardiac Resynchronization Therapy DeviceN/A1 trial
IMPROVE HF: Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient N/A1 trial
Implantable device: monitoring of intrathoracic impedance using the OptiVol diagnostic tool.N/A1 trial
Active Trials
NCT00279955Completed1,024Est. Jun 2008
NCT00303979Completed34,810Est. Aug 2009
NCT00400985Completed501Est. Aug 2009
+1 more trials
Stereotaxis
StereotaxisST.LOUIS, MO
1 program
1
Acute hemodynamic assessment using PV LoopsPhase 41 trial
Active Trials
NCT00370526Terminated100Est. Dec 2007
Abbott
AbbottABBOTT PARK, IL
3 programs
1
LevosimendanPhase 31 trial
Left Ventricular Assist SystemN/A1 trial
Thoratec HeartMate II Left Ventricular Assist SystemN/A1 trial
Active Trials
NCT00121485Completed200Est. Jan 2012
NCT00121472Completed194Est. May 2010
NCT00048425Completed600Est. Dec 2004
Cook Medical
Cook MedicalIN - Bloomington
1 program
1
Enhanced TrainingPhase 31 trial
Active Trials
NCT01698242CompletedEst. Dec 2015
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
APhase 2/31 trial
Active Trials
NCT00399594Completed96Est. Nov 2015
M&
Merck & Co.RAHWAY, NJ
2 programs
2
KW-3902IVPhase 21 trial
KW-3902IVPhase 21 trial
Active Trials
NCT00159614Completed30
NCT00159627Completed52
DS
Daiichi SankyoChina - Shanghai
1 program
1
CarperitidePhase 2Peptide1 trial
Active Trials
NCT00259038Completed162Est. Feb 2006
Novartis
NovartisBASEL, Switzerland
1 program
1
RelaxinPhase 21 trial
Active Trials
NCT00259116Completed18
Biotronik
BiotronikGermany - Berlin
1 program
Cardiac resynchronisation therapyN/A1 trial
Active Trials
NCT00376116Completed513Est. Nov 2008
NK
Nihon KohdenNEW YORK, NY
1 program
Non-invasive central venous pressureN/A1 trial
Active Trials
NCT06689215Active Not RecruitingEst. Mar 2027
Impulse Dynamics
Impulse DynamicsNY - Pearl River
1 program
OPTIMIZER SystemN/A1 trial
Active Trials
NCT00112125CompletedEst. Mar 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
StereotaxisAcute hemodynamic assessment using PV Loops
Rhythm PharmaceuticalsCRT-P or CRT-D Device
Cook MedicalEnhanced Training
AbbottLevosimendan
RocheA
NovartisRelaxin
Merck & Co.KW-3902IV
Merck & Co.KW-3902IV
Daiichi SankyoCarperitide
Nihon KohdenNon-invasive central venous pressure
Rhythm PharmaceuticalsIMPROVE HF: Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient
AbbottThoratec HeartMate II Left Ventricular Assist System
BiotronikCardiac resynchronisation therapy
Impulse DynamicsOPTIMIZER System
AbbottLeft Ventricular Assist System

Showing 15 of 17 trials with date data

Clinical Trials (17)

Total enrollment: 38,336 patients across 17 trials

NCT00370526StereotaxisAcute hemodynamic assessment using PV Loops

HEAL-HF: A Cardiac Resynchronization Therapy (CRT) Outcomes Study

Start: Feb 2007Est. completion: Dec 2007100 patients
Phase 4Terminated
NCT00157846Rhythm PharmaceuticalsCRT-P or CRT-D Device

X-Change HF - Exchange of the Existing Pacemaker/ICD in Bradycardia Patients Suffering From Heart Failure

Start: Oct 2003Est. completion: Aug 200836 patients
Phase 4Terminated
NCT01698242Cook MedicalEnhanced Training

The Congestive Heart Failure Adherence Redesign Trial

Start: May 2011Est. completion: Dec 2015
Phase 3Completed
NCT00048425AbbottLevosimendan

Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.

Start: Sep 2002Est. completion: Dec 2004600 patients
Phase 3Completed
NCT00399594RocheA

Effect of Targeting Left Ventricular Lead Position on the Rate of Response to Cardiac Resynchronization Therapy.

Start: Mar 2011Est. completion: Nov 201596 patients
Phase 2/3Completed
NCT00259116NovartisRelaxin

A Pilot Study of Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart Failure

Start: Nov 200518 patients
Phase 2Completed
NCT00159614Merck & Co.KW-3902IV

Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment

Start: Sep 200530 patients
Phase 2Completed
NCT00159627Merck & Co.KW-3902IV

Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).

Start: Aug 200452 patients
Phase 2Completed
NCT00259038Daiichi SankyoCarperitide

Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure

Start: Jan 2004Est. completion: Feb 2006162 patients
Phase 2Completed
NCT06689215Nihon KohdenNon-invasive central venous pressure

Comparison of Noninvasive vs. Invasive Hemodynamic Measurements

Start: Oct 2024Est. completion: Mar 2027
N/AActive Not Recruiting
NCT00303979Rhythm PharmaceuticalsIMPROVE HF: Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient

IMPROVE HF: Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting

Start: May 2005Est. completion: Aug 200934,810 patients
N/ACompleted
NCT00121472AbbottThoratec HeartMate II Left Ventricular Assist System

Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Bridge to Cardiac Transplantation

Start: Mar 2005Est. completion: May 2010194 patients
N/ACompleted
NCT00376116BiotronikCardiac resynchronisation therapy

Home Monitoring in Cardiac Resynchronisation Therapy

Start: Mar 2005Est. completion: Nov 2008513 patients
N/ACompleted
NCT00112125Impulse DynamicsOPTIMIZER System

Evaluation of the Safety and Effectiveness of the OPTIMIZER System in Subjects With Heart Failure: FIX-HF-5

Start: Feb 2005Est. completion: Mar 2019
N/ACompleted
NCT00121485AbbottLeft Ventricular Assist System

Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Destination Therapy

Start: Feb 2005Est. completion: Jan 2012200 patients
N/ACompleted
NCT00400985Rhythm PharmaceuticalsImplantable device: monitoring of intrathoracic impedance using the OptiVol diagnostic tool.

Sensitivity of the InSync Sentry OptiVol Feature for the Prediction of Heart Failure

Start: Jan 2005Est. completion: Aug 2009501 patients
N/ACompleted
NCT00279955Rhythm PharmaceuticalsCardiac Resynchronization Therapy Device

PARTNERS HF: Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure

Start: Jun 2004Est. completion: Jun 20081,024 patients
N/ACompleted

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Territory Sales Manager - Iowa / Nebraska

HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
19h ago
From $150K/yr

Clinical Consultant

Johnson & Johnson
North Ryde, New South Wales, Australia
20h ago

Regional Sales Specialist (Orange County / Long Beach, CA) - Johnson & Johnson MedTech, Electrophysiology

Johnson & Johnson
Irvine, California, United States of America
20h ago
$100K - $135K/yr

Trainee Technical Specialist

Johnson & Johnson
Leeds, West Yorkshire, United Kingdom
20h ago

Ingénieur d'Application Clinique (H/F) Dept. 54, 57, 67, 68, 25, 90

Johnson & Johnson
Issy-les-Moulineaux, France
20h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
11 companies competing in this space

Related Indications

Heart Failure(334)Hypertension(333)Coronary Artery Disease(295)Atrial Fibrillation(288)Pulmonary Arterial Hypertension(103)Acute Coronary Syndrome(62)Pulmonary Hypertension(55)Essential Hypertension(32)Coronary Heart Disease(28)Aortic Valve Stenosis(27)